Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01744171 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01744171 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT01744171, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with stage III-IV melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Vaccines made from peptides or antigens may help the body build an effective immune response to kill tumor cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-03-26 |
| Est. Completion | 2018-06-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01744171
The ClinicalTrials.gov registry entry for NCT01744171 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01744171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01744171 about?
NCT01744171 is a clinical study titled "Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma". This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with stage III-IV melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Vaccines made from peptides or antigens may help the body buil...
What is the current status of trial NCT01744171?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2013-03-26. Estimated completion is 2018-06-11.
What interventions are being tested in trial NCT01744171?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01744171?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.